NasdaqGM:STRO

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. More Details


Snowflake Analysis

Excellent balance sheet with limited growth.

Share Price & News

How has Sutro Biopharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: STRO's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

16.3%

STRO

6.7%

US Biotechs

0.09%

US Market


1 Year Return

11.9%

STRO

31.2%

US Biotechs

12.6%

US Market

Return vs Industry: STRO underperformed the US Biotechs industry which returned 31.2% over the past year.

Return vs Market: STRO matched the US Market which returned 12.6% over the past year.


Shareholder returns

STROIndustryMarket
7 Day16.3%6.7%0.09%
30 Day34.6%1.4%-1.6%
90 Day28.4%-1.2%7.9%
1 Year11.9%11.9%33.4%31.2%15.2%12.6%
3 Yearn/a17.9%12.2%38.9%29.6%
5 Yearn/a19.6%11.4%87.6%66.5%

Price Volatility Vs. Market

How volatile is Sutro Biopharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Sutro Biopharma undervalued compared to its fair value and its price relative to the market?

2.06x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate STRO's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate STRO's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: STRO is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: STRO is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate STRO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: STRO is good value based on its PB Ratio (2.1x) compared to the US Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Sutro Biopharma forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

-19.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: STRO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: STRO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: STRO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: STRO's revenue (25.4% per year) is forecast to grow faster than the US market (9.7% per year).

High Growth Revenue: STRO's revenue (25.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: STRO is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Sutro Biopharma performed over the past 5 years?

-28.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: STRO is currently unprofitable.

Growing Profit Margin: STRO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: STRO is unprofitable, and losses have increased over the past 5 years at a rate of 28.6% per year.

Accelerating Growth: Unable to compare STRO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: STRO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).


Return on Equity

High ROE: STRO has a negative Return on Equity (-8.43%), as it is currently unprofitable.


Next Steps

Financial Health

How is Sutro Biopharma's financial position?


Financial Position Analysis

Short Term Liabilities: STRO's short term assets ($258.5M) exceed its short term liabilities ($35.5M).

Long Term Liabilities: STRO's short term assets ($258.5M) exceed its long term liabilities ($35.3M).


Debt to Equity History and Analysis

Debt Level: STRO's debt to equity ratio (11.7%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if STRO's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: STRO has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: STRO has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 36.2% each year


Next Steps

Dividend

What is Sutro Biopharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate STRO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate STRO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if STRO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if STRO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of STRO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

7.7yrs

Average management tenure


CEO

Bill Newell (62 yo)

11.67yrs

Tenure

US$3,817,125

Compensation

Mr. William J. Newell, also known as Bill, J.D. has been the Chief Executive Officer and Director of Sutro Biopharma, Inc. since February 2009. He serves as Director at Vaxcyte, Inc. Since November 2013. M ...


CEO Compensation Analysis

Compensation vs Market: Bill's total compensation ($USD3.82M) is above average for companies of similar size in the US market ($USD1.99M).

Compensation vs Earnings: Bill's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
William Newell
CEO & Director11.67yrsUS$3.82m0.57%
$ 2.4m
Trevor Hallam
Chief Scientific Officer9.75yrsUS$1.03m0.047%
$ 199.1k
Arturo Molina
Chief Medical Officer4.58yrsUS$947.36k0.034%
$ 143.3k
Shabbir Anik
Chief Technical Operations Officer4.5yrsno data0.016%
$ 66.8k
James Swartz
Founder and Member of Scientific Advisory Board8.67yrsno datano data
Edward Albini
CFO & Secretary7.67yrsno data0.018%
$ 75.7k
Linda Fitzpatrick
Chief People & Communications Officer12.67yrsno data0.054%
$ 230.0k
Nicki Vasquez
Senior Vice President of Alliance Managementno datano datano data
Stephen Worsley
Chief Business Officer2yrsno datano data
Regina Cheng
Vice President of Finance & Controllerno datano datano data

7.7yrs

Average Tenure

62yo

Average Age

Experienced Management: STRO's management team is seasoned and experienced (7.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
William Newell
CEO & Director11.67yrsUS$3.82m0.57%
$ 2.4m
James Swartz
Founder and Member of Scientific Advisory Board8.67yrsno datano data
Connie Matsui
Independent Independent Chair of the Board1.25yrsUS$194.36k0%
$ 0
James Panek
Independent Independent Director0.67yrno data0%
$ 0
John Freund
Independent Director6.58yrsUS$121.68k0%
$ 0
Daniel Petree
Director11.08yrsUS$114.18k0.011%
$ 48.0k
Shalini Sharp
Independent Director1.83yrsUS$129.18k0%
$ 0
Carlos Paya
Chair of the Scientific Advisory Board0.33yrno datano data
Michael Dybbs
Independent Director2.17yrsUS$124.85k0%
$ 0
Joseph Lobacki
Independent Director3.58yrsUS$128.32k0%
$ 0
Lainie Martin
Member of the Clinical Advisory Board0.33yrno datano data

2.2yrs

Average Tenure

62yo

Average Age

Experienced Board: STRO's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 56.5%.


Top Shareholders

Company Information

Sutro Biopharma, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Sutro Biopharma, Inc.
  • Ticker: STRO
  • Exchange: NasdaqGM
  • Founded: 2003
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$425.525m
  • Shares outstanding: 35.88m
  • Website: https://www.sutrobio.com

Number of Employees


Location

  • Sutro Biopharma, Inc.
  • 310 Utah Avenue
  • Suite 150
  • South San Francisco
  • California
  • 94080
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
STRONasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDSep 2018
S09DB (Deutsche Boerse AG)YesCommon StockDEEURSep 2018

Biography

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated c ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/20 06:28
End of Day Share Price2020/09/18 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.